Your browser is no longer supported. Please, upgrade your browser.
JAZZ Jazz Pharmaceuticals plc daily Stock Chart
JAZZ [NASD]
Jazz Pharmaceuticals plc
Index- P/E37.78 EPS (ttm)4.77 Insider Own1.00% Shs Outstand59.49M Perf Week1.64%
Market Cap10.72B Forward P/E11.86 EPS next Y15.19 Insider Trans-5.98% Shs Float58.48M Perf Month7.80%
Income292.20M PEG2.29 EPS next Q3.23 Inst Own93.30% Short Float2.95% Perf Quarter19.54%
Sales1.69B P/S6.35 EPS this Y-15.30% Inst Trans-1.46% Short Ratio3.41 Perf Half Y34.88%
Book/sh46.50 P/B3.87 EPS next Y16.07% ROA8.90% Target Price184.83 Perf Year16.77%
Cash/sh11.90 P/C15.13 EPS next 5Y16.50% ROE17.60% 52W Range128.58 - 184.00 Perf YTD33.78%
Dividend- P/FCF18.69 EPS past 5Y4.60% ROI9.80% 52W High-2.10% Beta0.97
Dividend %- Quick Ratio2.90 Sales past 5Y22.50% Gross Margin92.90% 52W Low40.09% ATR3.90
Employees1210 Current Ratio3.00 Sales Q/Q18.20% Oper. Margin28.50% RSI (14)67.36 Volatility3.00% 2.06%
OptionableYes Debt/Eq0.57 EPS Q/Q-46.80% Profit Margin26.50% Rel Volume1.26 Prev Close183.18
ShortableYes LT Debt/Eq0.55 EarningsMay 08 AMC Payout0.00% Avg Volume504.59K Price180.13
Recom2.00 SMA203.96% SMA5010.12% SMA20021.01% Volume634,191 Change-1.67%
Mar-23-18Reiterated H.C. Wainwright Neutral $150 → $160
Mar-19-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-03-18Initiated Leerink Partners Outperform $180
Dec-05-17Reiterated Mizuho Neutral $144 → $150
Nov-10-17Resumed H.C. Wainwright Neutral $150
Nov-08-17Reiterated RBC Capital Mkts Outperform $210 → $195
Oct-19-17Initiated FBR & Co. Buy $206
Oct-05-17Initiated Morgan Stanley Equal-Weight $155
Sep-28-17Initiated Goldman Neutral $165
Aug-25-17Initiated H.C. Wainwright Neutral $144
May-31-17Reiterated Mizuho Neutral $150 → $144
May-15-17Initiated RBC Capital Mkts Outperform $210
Apr-06-17Downgrade Mizuho Buy → Neutral $162 → $150
Mar-21-17Reiterated Mizuho Buy $152 → $162
Feb-21-17Reiterated Mizuho Buy $127 → $152
Nov-09-16Reiterated Mizuho Buy $185 → $127
Aug-10-16Reiterated Mizuho Buy $195 → $185
Jul-19-16Reiterated Mizuho Buy $193 → $195
Jun-06-16Initiated Goldman Buy $196
May-11-16Upgrade Mizuho Neutral → Buy $137 → $193
Jun-19-18 08:55AM  5 Low-Beta Stocks to Buy as Trade Conflict Intensifies Zacks
Jun-18-18 07:32AM  Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA Zacks
Jun-15-18 10:03AM  5 Stocks Near 52-Week High With More Room to Run Zacks
09:23AM  5 Best Bargain PEG Stocks That Value Investors Love Zacks
07:09AM  Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar ACCESSWIRE
Jun-07-18 08:41AM  Jazz Pharmaceuticals (JAZZ) Up 16.9% Since Earnings Report: Can It Continue? Zacks
Jun-06-18 04:05PM  Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference PR Newswire
04:03PM  Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln Reuters
Jun-04-18 08:20AM  Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open Text, and ChemoCentryx New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jun-03-18 05:00PM  Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea PR Newswire
05:00PM  Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy PR Newswire
May-31-18 08:30AM  New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea PR Newswire
May-24-18 04:05PM  Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS PR Newswire
May-22-18 03:09PM  Jazz Securities Designated Activity Company -- Moody's assigns Ba1 to Jazz Pharma's senior secured credit facilities Moody's
06:31AM  3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists Motley Fool
May-14-18 07:10AM  Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks ACCESSWIRE
May-13-18 11:51PM  Edited Transcript of JAZZ earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 08:30AM  Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting PR Newswire
May-09-18 04:05PM  Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences PR Newswire +5.93%
10:32AM  Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates Zacks
06:00AM  3 Top Biotech Stocks to Buy in May Motley Fool
May-08-18 08:53PM  Jazz Pharmaceuticals to settle U.S. probe for $57 million Reuters
07:39PM  Jazz: 1Q Earnings Snapshot Associated Press
06:24PM  Jazz Pharmaceuticals Sets Aside $57 Million to Settle DOJ Probe Bloomberg
04:05PM  Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results PR Newswire
May-07-18 08:30AM  Drug/Biotech Q1 Earnings Lineup on May 8: JAZZ, ARNA & More Zacks
May-02-18 11:17AM  Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store? Zacks
May-01-18 08:30AM  Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients PR Newswire
Apr-30-18 05:27PM  Peninsula drug maker swings $110 million deal for voucher American City Business Journals
09:18AM  Voucher sale brings $110M payday for Spark Therapeutics American City Business Journals
Apr-24-18 04:05PM  Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018 PR Newswire
Apr-09-18 07:50AM  Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics, and SMART Global with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-19-18 09:37AM  Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential Benzinga
Mar-16-18 09:35AM  Should Value Investors Pick Jazz Pharmaceuticals (JAZZ) Stock? Zacks
Mar-14-18 07:35AM  New Research: Key Drivers of Growth for Jazz Pharmaceuticals, Armstrong World Industries, Banco Latinoamericano de Comercio Exterior, S.A, Mercury, Canadian National Railway, and Bank of Nova Scotia Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-07-18 02:31PM  Why Biotech Stocks Face Steep Declines Ahead Investopedia
Mar-06-18 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March PR Newswire
Mar-02-18 08:30AM  Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea PR Newswire
Feb-28-18 08:16PM  Edited Transcript of JAZZ earnings conference call or presentation 27-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
09:29AM  Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y Zacks
Feb-27-18 07:59PM  Jazz misses Street 4Q forecasts Associated Press
05:45PM  Jazz Pharma's Fourth-Quarter Sales, Profit Lag; Guidance Mixed Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results PR Newswire
12:20PM  Jazz Pharmaceuticals Plc to Host Earnings Call ACCESSWIRE
11:33AM  Jazz Pharmaceuticals Q4 Earnings Outlook Benzinga
07:00AM  Wired News - Jazz Pharma Enrolled First Patient in Phase-2 Clinical Trial Assessing Defibrotide for the Prevention of Acute Graft-versus-Host Disease ACCESSWIRE
Feb-25-18 03:50PM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Feb-23-18 08:30AM  Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease PR Newswire
Feb-21-18 10:30AM  Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect? Zacks
Feb-19-18 12:21PM  Interested In Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ)? Heres What Its Recent Performance Looks Like Simply Wall St.
Feb-13-18 04:05PM  Jazz Pharmaceuticals to Report 2017 Fourth Quarter and Full Year Financial Results on February 27, 2018 PR Newswire
Feb-12-18 03:50PM  Why ImmunoGen Jumped Higher Today Motley Fool
Feb-08-18 04:15PM  National Comprehensive Cancer Network® adds Jazz Pharmaceuticals' Vyxeos (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology PR Newswire
Jan-15-18 03:10PM  Concert Pharmaceuticals Plunges on Patent Petition Setback Zacks
Jan-12-18 08:05AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Jan-05-18 07:35AM  How Jazzs Erwinaze, Defitelio, and Prialt Performed in 3Q17 Market Realist
Jan-04-18 12:20PM  How Is Jazz Pharmaceuticals Xyrem Positioned after 3Q17? Market Realist
10:50AM  How Did Jazz Pharmaceuticals Perform in 3Q17? Market Realist
09:17AM  How Analysts Rated Jazz Pharmaceuticals in December Market Realist
Jan-02-18 04:05PM  Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8 PR Newswire
08:05AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Dec-26-17 11:42AM  ETFs with exposure to Jazz Pharmaceuticals Plc : December 26, 2017 Capital Cube
Dec-25-17 09:29AM  Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-22-17 08:28AM  Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder Zacks
Dec-21-17 08:30AM  Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea PR Newswire
Dec-20-17 06:00AM  The Loopholes Drug Companies Use to Keep Prices High Bloomberg
Dec-19-17 07:55PM  Can Jazz Pharmaceuticals Public Limited Companys (NASDAQ:JAZZ) ROE Continue To Surpass The Industry Average? Simply Wall St.
Dec-15-17 03:28PM  Pennsylvania man admits to trading on tips about drug company Reuters
03:03PM  Pennsylvania man admits to trading on tips about drug company Reuters
Dec-14-17 11:02AM  December Top Growth Stocks Simply Wall St.
Dec-13-17 02:35PM  Jazz Pharmaceuticals Plc Value Analysis (NASDAQ:JAZZ) : December 13, 2017 Capital Cube
Dec-12-17 07:24AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : December 12, 2017 Capital Cube
Dec-08-17 08:05AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Dec-07-17 04:05PM  Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference PR Newswire
Dec-04-17 04:29PM  Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018 GlobeNewswire
04:05PM  Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer PR Newswire
Nov-29-17 12:17PM  Drug Charity May Shutter After U.S. Faults Pharma Influence Bloomberg
Nov-22-17 08:05AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Nov-21-17 08:05AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Nov-15-17 07:20AM  Corporate News Blog - RXi Pharma Collaborates with Gustave Roussy, Europe's Leading Cancer Centre ACCESSWIRE
Nov-14-17 08:06AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
07:40AM  Featured Company News - Adaptimmune Outlines Study Designs for Two T-Cell Clinical Trials - MAGE-A4 and NY-ESO SPEAR ACCESSWIRE
Nov-13-17 08:05AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Nov-10-17 10:46AM  Edited Transcript of JAZZ earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 04:05PM  Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences PR Newswire
Nov-08-17 12:21PM  Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut Zacks
Nov-07-17 05:47PM  Jazz tops 3Q profit forecasts Associated Press -5.30%
04:05PM  Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results PR Newswire
08:08AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Nov-06-17 08:05AM  See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC. Markit
Nov-03-17 08:30AM  Jazz Pharmaceuticals Submits Vyxeos Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia PR Newswire
Nov-01-17 09:16AM  Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting PR Newswire
Oct-31-17 10:19AM  Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store? Zacks
Oct-26-17 06:00PM  What Is Jazz Pharmaceuticals Public Limited Companys (JAZZ) Share Price Doing? Simply Wall St.
Oct-24-17 04:05PM  Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017 PR Newswire
Oct-23-17 10:44AM  ETFs with exposure to Jazz Pharmaceuticals Plc : October 23, 2017 Capital Cube
Oct-13-17 10:20AM  All that Jazz: Why this Palo Alto drug maker is growing American City Business Journals
Oct-11-17 11:42AM  ETFs with exposure to Jazz Pharmaceuticals Plc : October 11, 2017 Capital Cube
Oct-06-17 08:35AM  Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8% Zacks
Oct-03-17 08:17AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : October 3, 2017 Capital Cube
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Young Matthew P.EVP & CFOJun 15Sale176.99700123,89335,568Jun 19 04:26 PM
MILLER MICHAEL PATRICKEVP, US CommercialJun 14Sale176.5320035,30625,972Jun 18 04:37 PM
Young Matthew P.EVP & CFOJun 01Option Exercise58.725,000293,60041,268Jun 05 06:52 PM
Young Matthew P.EVP & CFOJun 01Sale170.045,000850,21236,268Jun 05 06:52 PM
COZADD BRUCE CChairman & CEOJun 01Sale168.867,0001,182,040285,715Jun 05 06:50 PM
Young Matthew P.EVP & CFOMay 15Sale164.641,420233,78936,203May 16 04:54 PM
MILLER MICHAEL PATRICKEVP, US CommercialMay 14Sale164.6820032,93626,122May 15 05:24 PM
WILSON KAREN JSVP, Finance & PAOMay 11Sale165.003,760620,40015,757May 15 05:27 PM
COZADD BRUCE CChairman & CEOMay 01Sale151.571,000151,570292,542May 03 04:57 PM
Young Matthew P.EVP & CFOApr 16Sale156.01700109,20738,465Apr 18 05:09 PM
MILLER MICHAEL PATRICKEVP, US CommercialApr 13Sale157.4920031,49827,481Apr 13 05:22 PM
WILSON KAREN JSVP, Finance & PAOApr 10Sale155.003,899604,34519,517Apr 12 04:25 PM
COZADD BRUCE CChairman & CEOApr 02Sale150.011,000150,010293,542Apr 04 05:49 PM
Young Matthew P.EVP & CFOMar 15Sale151.22700105,85439,165Mar 19 04:44 PM
MILLER MICHAEL PATRICKEVP, US CommercialMar 14Sale151.1220030,22427,681Mar 16 05:10 PM
COZADD BRUCE CChairman & CEOMar 09Sale150.001,000150,000294,542Mar 13 05:27 PM
Treacy PaulSVP, Technical OperationsMar 06Sale141.4759484,03018,641Mar 07 04:10 PM
Young Matthew P.EVP & CFOMar 06Sale142.361,152163,99839,865Mar 07 04:10 PM
Treacy PaulSVP, Technical OperationsMar 02Sale139.62877122,44619,235Mar 05 04:39 PM
Young Matthew P.EVP & CFOFeb 28Sale148.821,219181,41132,965Feb 28 05:57 PM
COZADD BRUCE CChairman & CEOFeb 28Sale150.001,000150,000262,830Feb 28 05:24 PM
Young Matthew P.EVP & CFOFeb 27Sale145.601,916278,96934,790Feb 28 05:57 PM
MILLER MICHAEL PATRICKEVP, US CommercialFeb 14Sale139.9920027,99821,469Feb 16 05:31 PM
Young Matthew P.EVP & CFOJan 16Sale152.16700106,51238,959Jan 18 05:05 PM
MILLER MICHAEL PATRICKEVP, US CommercialJan 12Sale148.6520029,73021,669Jan 17 04:55 PM
COZADD BRUCE CChairman & CEOJan 12Sale150.003,000450,000273,737Jan 17 04:53 PM
ENRIGHT PATRICK GDirectorDec 11Option Exercise64.309,000578,65525,339Dec 13 05:52 PM
Cox Russell J.EVP & COODec 11Option Exercise13.6350,758691,676102,821Dec 13 05:53 PM
ENRIGHT PATRICK GDirectorDec 11Sale139.739,0001,257,58216,339Dec 13 05:52 PM
MILLER MICHAEL PATRICKEVP, US CommercialDec 11Sale139.1520027,83021,869Dec 13 05:56 PM
McGill IainSVP, Europe & Rest of WorldNov 17Option Exercise46.838,000374,64028,383Nov 21 05:29 PM
McGill IainSVP, Europe & Rest of WorldNov 17Sale133.428,0001,067,35820,383Nov 21 05:29 PM
ENRIGHT PATRICK GDirectorNov 17Sale133.1935246,8831,365Nov 21 05:27 PM
COZADD BRUCE CChairman & CEOOct 02Sale150.001,000150,000276,664Oct 04 05:03 PM
COZADD BRUCE CChairman & CEOSep 12Sale153.521,000153,520277,664Sep 13 07:06 PM
ENRIGHT PATRICK GDirectorAug 25Sale148.4035152,0881,717Aug 28 06:10 PM
MILLER MICHAEL PATRICKEVP, US CommercialAug 15Sale144.3820028,87621,996Aug 16 07:17 PM
Treacy PaulSVP, Technical OperationsAug 14Sale143.321,304186,88416,385Aug 15 04:59 PM
Winningham Rick EDirectorAug 11Sale142.3766294,24811,094Aug 14 05:34 PM
Sohn Catherine A.DirectorAug 11Sale142.3766294,2486,819Aug 14 05:33 PM
Schnee ElmarDirectorAug 11Sale142.371,199170,6995,341Aug 14 05:29 PM
RIEDEL NORBERT GDirectorAug 11Sale142.3766294,2485,656Aug 14 05:27 PM
O'Keefe Kenneth WDirectorAug 11Sale142.3766294,24812,810Aug 14 05:25 PM
McSharry Heather AnnDirectorAug 11Sale142.37717102,0776,724Aug 14 05:21 PM
Gray PeterDirectorAug 11Sale142.37717102,0787,402Aug 14 05:19 PM
ENRIGHT PATRICK GDirectorAug 11Sale142.3766294,2482,068Aug 14 05:17 PM
BERNS PAUL LDirectorAug 11Sale142.3766294,2485,937Aug 14 05:15 PM
Hooper Suzanne SawochkaEVP & General CounselJul 20Sale160.004,580732,80032,322Jul 21 05:47 PM
MILLER MICHAEL PATRICKEVP, US CommercialJul 17Sale154.9720030,99422,196Jul 18 06:19 PM
Hooper Suzanne SawochkaEVP & General CounselJun 23Sale160.0042067,20036,902Jun 26 07:19 PM